Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s...
-
OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update. 2020...
-
OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center...
-
OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be...
-
OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM’s Chief Executive Officer, has been invited to present at the...
-
OCALA, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of...
-
美国佛罗里达州奥卡拉, March 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽交所代码：AIM）今天宣布已给第1期临床研究的首批健康受试者用药，以研究AIM的药物安普利近（Ampligen）作为一种潜在鼻内疗法的安全性。AIM的目标是开发安普利近，将其作为一种新冠病毒和其他呼吸道病毒性疾病的鼻内预防或早期治疗药物。 ...
-
OCALA, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the...
-
佛羅里達州奧卡拉, March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) 今天宣佈其子公司 NV Hemispherx Biopharma Europe 已獲得歐盟委員會的正式通知，Ampligen 已獲治療胰臟癌的孤兒藥品認證。 ...
-
佛罗里达州奥卡拉, March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（NYSE American：AIM）今天宣布，其子公司NV Hemispherx Biopharma Europe获得欧盟委员会（EC）的正式通知，批准该公司Ampligen作为胰腺癌的治疗方法的孤儿药产品申请。 ...